Overview
- Elon Musk said on X that Neuralink plans to start high-volume manufacturing in 2026 and shift implantation to an almost entirely automated process.
- Muske stated that device threads would be inserted through the dura without removing it, a claimed advance tied to the company’s surgical robot.
- Neuralink began human trials in 2024 after the FDA initially rejected an application in 2022, reflecting a stepwise regulatory path.
- In September 2025 the company reported 12 implanted participants actively using the device, with demonstrations including cursor control, gaming, and online browsing.
- Neuralink raised $650 million in a 2025 Series E round to fund scale-up, and it has signaled additional 2026 milestones such as a first vision-restoration trial called Blindsight.